Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

A drug treatment used for cirrhosis of the liver may also be beneficial for frontotemporal dementia

Staff Writer
Staff Writer 3 years ago
Updated 2020/10/14 at 8:29 PM
Share
SHARE

A team of researchers at the University of York showed that a drug treatment often used for cirrhosis of the liver might be beneficial for the treatment of frontotemporal dementia (FTD).

The study, published in Neurobiology of Disease, utilized brain cells from rodents and fruit flies to model the neurodegeneration process associated with frontotemporal dementia.

In their new findings, the commonly used drug treatment Ursodeoxycholic Acid could increase new proteins identified by researchers that protect neurons from extinction.

“The mechanism of action for this drug is currently unknown and the work we will now do to increase our understanding of how it works may help us lengthen and improve the lives of patients with FTD and potentially other neurodegenerative conditions too,” Sean Sweeney, co-author of the study, commented in a news release.

The drug treatment, commonly used for cirrhosis of the liver, was shown to be beneficial for the treatment of frontotemporal dementia and motorneuron disease, according to the findings.

“Currently, there’s no way to slow down or cure frontotemporal dementia, one of the most common forms of dementia in people under 65, so we’re excited to see an existing drug stopping brain cells from dying. While this is in the early stages, it’s a valuable first step on the road to finding a way to improve the lives of people with FTD and help them live longer,” Fiona Carragher of Alzheimer’s Society stated in a news release.

Photo: Neurology Advisor

You Might Also Like

Study boasts MDMA-assisted therapy for PTSD patients

How the brain is organized is revealed by the largest genetic study of brain structure to date

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

New study reveals positive results from postpartum depression treatment Zuranolone

New study explores magic mushrooms for anorexia nervosa psychopathology

TAGGED: frontotemporal dementia, Ursodeoxycholic Acid
Staff Writer September 15, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article People who experience PTSD may be at a higher risk of dementia
Next Article Women are more depressed in societies not advocating for gender equality

Recommended

Clinical

Study boasts MDMA-assisted therapy for PTSD patients

1 Min Read
Clinical

How the brain is organized is revealed by the largest genetic study of brain structure to date

2 Min Read
Clinical

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

3 Min Read
Clinical

New study reveals positive results from postpartum depression treatment Zuranolone

2 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?